A Clinical Trial for Post Traumatic Stress Disorder (MATTER)
Recruitment status was Recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
he purpose of this study is to test whether a medication, called mifepristone (commonly known as the ³Morning-After-Pill²), can help to prevent emotional problems after someone has survived a traumatic experience. We are studying this medication for the treatment of Post-traumatic Stress disorder (PTSD.
| Condition | Intervention | Phase |
|---|---|---|
|
Post Traumatic Stress Disorder (PTSD) |
Drug: Medicane (mifepristone) Drug: Placebo |
Phase 1 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | Mifepristone After Trauma to Enhance Resilience |
- Clinical Administered PTSD Scale(CAPS) [ Time Frame: once a week over eight weeks ]
| Estimated Enrollment: | 8 |
| Study Start Date: | September 2007 |
| Estimated Study Completion Date: | August 2008 |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: 1
Medicane (mifepristone)
|
Drug: Medicane (mifepristone)
2 doses of 1200mg, Administered 2-3 days apart
|
|
Placebo Comparator: 2
Placebo
|
Drug: Placebo
2 doses of 1200mg, administered 2-3 days apart
|
Detailed Description:
PTSD is an emotional illness that can develop in people after they have experienced a traumatic event. It involves symptoms such as poor sleep, nightmares about the trauma, unwanted daytime memories of the trauma (flashbacks), jumpiness, and trouble looking forward to things in the future. Once people develop PTSD, the symptoms tend to last a very long time.
We are testing the idea that mifepristone, which blocks the effect of the hormones progesterone and cortisol, will help treat PTSD. Progesterone is a hormone made in the bodies of both men and women and its main role is in regulating the menstrual cycle and in pregnancy. Cortisol is also a hormone made in the body of both men and women and helps the body respond to stress. Cortisol also has a role in making emotional memories more intense than other memories. We are testing whether blocking the effect of cortisol with mifepristone as you recall your trauma may be able to decrease the intensity of your traumatic memories. This medication will not completely block out your memories of the traumatic experience but may decrease how much your thoughts are drawn back to the memory of the traumatic event.
Eligibility| Ages Eligible for Study: | 18 Years to 65 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Male or Female
- Between 18 and 65 years old
- Have experienced one or more traumatic events within the last year €Examples for traumatic events include physical or sexual assault, combat, natural disasters, witnessing death or injury of another person, bereavement €Currently experiencing severe symptoms of anxiety including flashbacks and intrusive memories of the traumatic event. €Not currently pregnant or intending to become pregnant. If sexually active, participants must be using an approved form of birth control
- Medically healthy
- Not currently taking psychiatric medications
Exclusion Criteria:
- > Lifetime or current diagnosis of schizophrenia or other psychotic disorder, bipolar disorder, or current Axis I disorder (except for major depression secondary to the PTSD)
- Current evidence or history of significant unstable medical illness or organic brain impairment, including stroke, CNS tumor, demyelinating disease, cardiac, pulmonary, gastrointestinal, or renal or hepatic impairment.
- Patient who in the investigator¹s judgment pose a current suicidal or homicidal risk
- DSM-IV substance abuse or dependence within the past 90 days
- Patient has been taking psychotropic medication in the last 2 weeks (5 weeks for fluoxetine) prior to screening. Psychotropic medications in the last 2 weeks prior to screening, fluoxetine in last 5 weeks.
- Treatment with any other concomitant medication with primarily CNS activity
- Treatment with any medication that the PI considers not acceptable for this study.
- Patient regularly, or on average, drinks more than a) 28 units of alcohol per week for male patients, or b) 21 units of alcohol per week for female patients (1 unit = 1/2 pint of beer, or 1 glass of wine, or 1 measure of spirit)
- Pregnancy or lactation*
- Patient is currently receiving evidenced-based structured psychotherapy (e.g., cognitive-behavioral therapy, exposure therapy).
Contacts and Locations| Contact: Douglas Brodman, BA | 212-241-6603 | Douglas.brodman@mssm.edu |
| United States, New York | |
| Mount Sinai School of Medicine | Recruiting |
| New York, New York, United States, 10029 | |
| Principal Investigator: | Antonia New, MD | Mount Sinai School of Medicine |
More Information
Additional Information:
No publications provided
| ClinicalTrials.gov Identifier: | NCT00554177 History of Changes |
| Other Study ID Numbers: | GCO# 07-0900 |
| Study First Received: | November 2, 2007 |
| Last Updated: | March 10, 2009 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by Mount Sinai School of Medicine:
|
sexual combat PTSD Clinical trial |
Trauma PTSD treatment PTSD medication Post traumatic stress disorder |
Additional relevant MeSH terms:
|
Stress Disorders, Post-Traumatic Stress Disorders, Traumatic Anxiety Disorders Mental Disorders Mifepristone Contraceptives, Oral, Synthetic Contraceptives, Oral Contraceptive Agents, Female Contraceptive Agents Reproductive Control Agents Physiological Effects of Drugs |
Pharmacologic Actions Therapeutic Uses Contraceptives, Postcoital, Synthetic Contraceptives, Postcoital Hormone Antagonists Hormones, Hormone Substitutes, and Hormone Antagonists Luteolytic Agents Menstruation-Inducing Agents Abortifacient Agents, Steroidal Abortifacient Agents |
ClinicalTrials.gov processed this record on May 23, 2013